Health · 2 views

Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis

Source Summary Published 1h 56m ago Brief Under 1 min brief

Story intelligence

Coverage Single outlet Single-outlet story

Views 2 Community interest

Brief read Under 1 min brief 26 words

Summary

(MedPage Today) -- The investigational Bruton's tyrosine kinase (BTK) inhibitor fenebrutinib may curb chronic active lesions in multiple sclerosis (MS), data from phase III trials suggested.

Read original at MedPage Today

Medical Xpress59m ago2 views
Low-carb diet high in saturated fat shows mixed effects on cholesterol in two-year trialContinue reading
MedPage Today2h ago1 view
Congress Mulls Ways to Fix the Surprise Billing LawContinue reading
Medical Xpress2h ago2 views
How our blood vessels age from withinContinue reading
MedPage Today3h ago2 views
AI May Help Detect Rare Sperm in Men With AzoospermiaContinue reading

Support HappeningNow

Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.

Support HappeningNow

Report an issue with this page

HAPPENING NOW

Fenebrutinib May Curb Chronic Active Lesions in Multiple Sclerosis

More from Health